Anhui Fengyuan Pharmaceutical Co., Ltd. (SZSE:000153) agreed to acquire Anhui Tiger Biotech Co., Ltd. from Anhui Taige Biological Technology Co., Ltd. on April 7, 2023. Under the terms, consideration will paid in CNY 7.71 per share in cash. Transaction is subject to approval from Anhui Fengyuan's shareholders, board.

stock exchange and CRCS. For the period ended 2022, Anhui Tiger Biotech had CNY 392.58 million of total assets, CNY 145.18 million of net assets, CNY 219.94 million of revenue, CNY 35.91 million operating profit and CNY 32.60 million of Net Profit.